Michael Keyoung, MD, PhDHead of North America at C-Bridge Capital
Michael has over 20 years of experience as a physician, investor and a healthcare executive. He is currently Managing Director and Head of North America at CBC Group (formerly C-Bridge Capital) where he invests out of both private equity and royalty credit funds. Prior to joining C-Bridge Capital, he was President and CEO of Genexine Inc., $2Bn market cap KOSDAQ listed clinical stage biotech company developing innovative biologics in immuno-oncology, metabolic and autoimmune diseases. Michael is Founding Managing Partner of Portola Capital Partners, a healthcare-dedicated investment and advisory firm, and previously served as President of Catalyst Biosciences (NASDAQ:CBIO), Orphan diseases and Ophthalmology focused clinical stage biotech company. Michael is and has served on the board of directors of AffaMed Therapeutics, Everest Medicines, I-Mab BioPharma, InxMed and Tasgen, which have been funded by CBC Group. Michael received his Medical Doctorate and PhD in Neuroscience and Neurology from Cornell University Weill Medical College and Memorial Sloan Kettering Cancer Center as part of Tri-Institutional Medical Scientist Training Program. He was a Howard Hughes Medical Institute fellow and received his clinical surgical training at the University of California, San Francisco.